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Abstract
Background: There is considerable interest in identifying compounds that can improve glucose homeostasis. Skeletal
muscle, due to its large mass, is the principal organ for glucose disposal in the body and we have investigated here if
shikonin, a naphthoquinone derived from the Chinese plant Lithospermum erythrorhizon, increases glucose uptake in
skeletal muscle cells.
Methodology/Principal Findings: Shikonin increases glucose uptake in L6 skeletal muscle myotubes, but does not
phosphorylate Akt, indicating that in skeletal muscle cells its effect is medaited via a pathway distinct from that used for
insulin-stimulated uptake. Furthermore we find no evidence for the involvement of AMP-activated protein kinase in
shikonin induced glucose uptake. Shikonin increases the intracellular levels of calcium in these cells and this increase is
necessary for shikonin-mediated glucose uptake. Furthermore, we found that shikonin stimulated the translocation of
GLUT4 from intracellular vesicles to the cell surface in L6 myoblasts. The beneficial effect of shikonin on glucose uptake was
investigated in vivo by measuring plasma glucose levels and insulin sensitivity in spontaneously diabetic Goto-Kakizaki rats.
Treatment with shikonin (10 mg/kg intraperitoneally) once daily for 4 days significantly decreased plasma glucose levels. In
an insulin sensitivity test (s.c. injection of 0.5 U/kg insulin), plasma glucose levels were significantly lower in the shikonin-
treated rats. In conclusion, shikonin increases glucose uptake in muscle cells via an insulin-independent pathway dependent
on calcium.
Conclusions/Significance: Shikonin increases glucose uptake in skeletal muscle cells via an insulin-independent pathway
dependent on calcium. The beneficial effects of shikonin on glucose metabolism, both in vitro and in vivo, show that the
compound possesses properties that make it of considerable interest for developing novel treatment of type 2 diabetes.
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Introduction
Due to the increasing number of people with type 2 diabetes
mellitus (an estimated 285 million people, corresponding to 6.4%
of the world’s adult population in 2010), there is considerable
interest in identifying compounds that can improve glucose
tolerance. Extracts from the dried gromwell root (Lithospermum
erythrorhizon) have been used in traditional Chinese medicine to
treat a variety of disorders involving inflammation and cancer and
the key active substance in the gromwell root has been shown to be
the napthoquinone shikonin [1]. Interestingly, shikonin has been
reported to increase glucose uptake in adipocyte 3T3-L1 cells,
primary rat adipocytes and cardiomyocytes [2], by enhancing both
insulin signaling as well as increasing glucose uptake by itself [2],
and inhibiting fat accumulation in 3T3-L1 adipocytes [3]. The
mechanisms whereby shikonin increases glucose uptake into
adipocytes are not fully understood. Insulin increases glucose
uptake in adipocytes and skeletal muscle cells by increasing the
translocation of intracellular vesicles containing GLUT4 to the cell
surface by a mechanism dependent upon activation of phospha-
tidylinositol 3-kinase (PI3K) and Akt [4]. Previous studies have
shown that shikonin increases glucose uptake in adipocytes
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e22510independently of the insulin receptor, IRS proteins and PI3K but
through an unidentified tyrosine kinase mediated mechanism
requiring Akt phosphorylation [2]. In CHO cells transfected with
the insulin receptor, shikonin inhibited PTEN which may explain
some of its insulin like actions such as increased glucose uptake [5].
Glucose uptake into muscle fibers provides the cells with
important energy substrate and has major impact on whole body
glucose homeostasis. Thus there are several signals, extra- as well
as intracellular, that can regulate glucose uptake in muscle cells.
The major hormone regulating glucose uptake in skeletal
muscles is insulin that is secreted after a meal in order to decrease
blood glucose levels. When insulin binds the insulin receptor it
induces an intracellular signaling cascade, resulting in transloca-
tion of the glucose transporter GLUT4 to the plasma membrane
and consequently increased glucose uptake. However, in type 2
diabetes, insulin sensitivity is decreased in extrahepatic tissues,
mainly skeletal muscle, leading to markedly impaired insulin
activation of the insulin signaling cascade and GLUT4-transloca-
tion. Thus it is of great importance to find and characterize
insulin-independent pathways stimulating glucose uptake in
skeletal muscle. For example, the hormone epinephrine and the
neurotransmitter norepinephrine can induce glucose uptake in
skeletal muscles independently of insulin. These molecules can act
both on a- and b-adrenoceptors and further characterization of
the signaling shows that both receptor subtypes, although utilizing
different intracellular signaling cascades, will mediate glucose
uptake through Akt independent pathways [6,7]. Furthermore,
activation of the M3 muscarinic acetylcholine receptor can induce
glucose uptake in myotubes by a CaMKK-AMPK-dependent
mechanism [8].
Other intracellular signalling intermediates besides PI3K/Akt
can affect glucose uptake e.g. AMPK (AMP activated protein
kinase), ROS and hypoxia. The most well described of these
signals is AMPK, AMP activated kinase, which functions as an
energy sensor. It can be activated by several different mechanisms,
including an increased AMP/ATP-ratio, allosteric activation by
AMP or or via activation of 3 identified upstream kinases (AMPK-
kinase) [9]. AMPK can regulate glucose uptake due to stress, via
activation of GPCRs (see [10]) or after activation by pharmaco-
logical agents such as 5-aminoimidazole-4-carboxamide 1 b-D-
ribonucleoside (AICAR) which is used widely as a pharmacolog-
ical activator of AMPK. Importantly increases in glucose uptake
through AMPK activation are sought for the treatment of type 2
diabetes since the AMPK signaling pathway is not down regulated
in type 2 diabetes (as opposed to the insulin signaling pathway) and
pharmacological agents such as metformin used clinically for the
treatment of type 2 diabetes exert some of their actions through
AMPK.
Contraction of skeletal muscles (such as that occurring during
exercise) also leads to increased glucose uptake. This is in part due
to AMPK-activation but also on non-AMPK mediated mecha-
nisms which may include ROS and NO production [11], and
importantly increases in intracellular Ca
2+ levels[12]. Further-
more, increased calcium levels can induce glucose uptake also
independently of contraction [13] and calcium ionophores are
shown to increase glucose uptake in in L6 skeletal muscle cells as
well as in primary skeletal muscle myoblast cultures [14,15].
There are several mechanisms whereby Ca
2+ can induce
glucose uptake. Ca
2+ and calcium-calmodulin dependent protein
kinases (CaMKKs) can, be upstream regulators of both AMPK-
and Akt-activity, but there is evidence that calcium can increase
glucose uptake independently of AMPK or Akt. For example,
Ca
2+-elevating agents such as caffeine increase glucose uptake in
skeletal muscle by a mechanism additive to AMPK-activation
[16], inhibition of CaMKII via in vivo electroporation of CaMKII
inhibitory peptide into mouse tibialis anterior muscles decreased
contraction-induced muscle glucose uptake significantly without
affecting phosphorylation of Akt-substrates or AMPK [17] and
expression of constitutively active CaMKKa in mouse muscles
increased glucose uptake 2.5 fold without affecting Akt-phosphor-
ylation. This effect on glucose uptake was also seen in mice with
imparied AMPK-function, indicating that there is an AMPK-
independent pathway [18]. Thus calcium can induce glucose
uptake in muscles via both AMPK-dependent and –independent
mechanisms.
We examined the possible effect of shikonin on glucose uptake
in skeletal muscle as well as on total body glucose homeostasis.
Skeletal muscle, due to its large mass, is the principal organ for
glucose disposal in the body and therefore effects on skeletal
muscle cells can have profound effects on glucose homeostasis. We
have utilized the L6 skeletal muscle cell line (commonly used for
studies of glucose uptake [19]) to investigate whether shikonin
affects glucose uptake and the mechanism whereby this occurs.
Further, we have investigated the effect of shikonin on plasma
glucose levels and insulin tolerance in diabetic animals, using the
Goto-Kakizaki (GK) rat as a model of non-obese type 2 diabetes
[20,21]. The GK rat develops hyperglycemia post-natally and
maintains moderately enhanced plasma glucose levels during its
lifetime. Like in human type 2 diabetes, the glucose intolerance in
the GK rat is due partly to impaired insulin secretion, but also to
reduced insulin sensitivity in target tissues. We show that shikonin
increases GLUT4-translocation and glucose uptake in L6 skeletal
muscle cells, independently of Akt-AMPK but dependent upon
calcium increases, and improves glucose tolerance in vivo.
Materials and Methods
Animals
Diabetic Goto-Kakizaki (GK) male rats were bred at the
Department of Molecular Medicine and Surgery (Karolinska
Institute, Stockholm, Sweden) [20]. The animals were kept at
22uC with free access to food and water. All experiments were
conducted with the permission of the North Stockholm Animal
Ethics Committee. Six male GK rats, 6 weeks old and weighing
100–200 g, were initially given intraperitoneally (i.p.) vehicle
(DMSO/olive oil) (9:1), once daily for 4 days. In the same 6 rats
after one week of the vehicle experiments, shikonin (20 mg/ml) at
a dose of 10 mg/kg (500 ml/kg) was injected i.p. once daily at 9
am for 4 subsequent days. Rats were unanaestesized during the
whole procedure. Plasma samples were obtained by tail snipping.
Plasma glucose levels were measured by glucometer (Accu- Chek
Aviva). On the 4
th day (one hour after the i.p. injection of the
vehicle and shikonin), insulin (Actrapid) was injected subcutane-
ously (s.c.) at a dose of 0.5 U/kg, and plasma glucose levels were
measured before the injection of insulin and every 15 min for
2 hours and then every 30 minutes for 2 hours.
Ethics Statement
Approved by the Stockholm North Ethical Committee on
Animal Research (Dnr N65/06).
Cell culture
L6 cells (from ATCC) were grown in DMEM (4.5 g/liter
glucose) supplemented with 10% (vol/vol) fetal bovine serum,
10 mM HEPES buffer, 2 mM L-Glutamine, 50 U/ml penicillin
and 50 mg/ml streptomycin at 37uC with 8% CO2. Upon
reaching confluence, differentiation was induced by media
containing 2% (v/v) fetal bovine serum for 7 days.
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3H]-D-glucose uptake assay
Glucose uptake in L6 cells was measured using the 2-deoxy-
[
3H]-D-glucose method [22] with some modifications [14], except
that for cells treated for 20 h, cells were treated with the
appropriate drug in serum free media for 19 h 30 min, cells
washed in warm phosphate-buffered saline, and media replaced to
glucose free media for 10 min before adding 50 nM 2-deoxy-[
3H]-
D-glucose for 6–10 min. When inhibitors were used, the time
indicated with the results represents the time cells were pre-
equilibrated with the inhibitors before agonists were added.
Western blot analysis for AMPK and Akt
Cells were serum-starved overnight before each experiment and
exposed to drugs for times and concentrations indicated with the
data. Cells were harvested and run on polyacrylamide gels as
described previously [23] and electro transferred to Hybond-P
PVDF membranes (pore size 0.45 mm; Amersham Pharmacia
Biotech). Primary antibodies used were AMPK, phospho-AMPK
(Thr172), Akt, phospho-Akt (Ser473), phospho-Akt (Thr308),
(diluted 1:1000 except phospho-AMPK diluted 1:500), which
were detected using a secondary antibody (HRP linked anti-rabbit
IgG, diluted 1:2000) and chemiluminescence (ECL, Amersham
Pharmacia Biotech). All antibodies were purchased from Cell
Signalling.
Quantification of blots was preformed by the software
MacBiophotonics ImageJ (McMaster Biophotonics Facility,
McMaster University, Canada).
ATP level measurements
L6-myotubes were serum starved over night, new medium was
added for 2 h before stimulation with drugs for 2 h. Cell extracts
were isolated and the AMP-to-ATP ratio was measured as
previously described [24]. Results are expressed as nanomoles
ATP per milligram protein.
Oxygen consumption
Differentiated L6 cells were treated for 2 h with 1 mM shikonin
and harvested by trypsin digestion. Oxygen consumption rates
were monitored with a Clark-type oxygen electrode (Yellow
Springs Instruments Company, Yellow Springs OH, U.S.A.) in a
sealed chamber at 37uC. L6 cells were added to a magnetically
stirred oxygen electrode chamber containing DMEM in a final
volume of 1.1 ml. The output signal from the oxygen electrode
amplifier was collected by a PowerLab/ADInstrument (applica-
tion program Chart v5.1.1.). The Chart data files were converted
to absolute values, based on an oxygen content of 217 nmol of O2
per 1 ml of water, and on the number of cell used. For calculation
of stable oxygen consumption rates, mean values during about
1 min were obtained from these recordings.
Mitochondria from mouse skeletal muscles were prepared and
analysed as previously described [25].
Ca
2+-measurements
Cytosolic free [Ca
2+] ([Ca
2+]i) was measured during exposure to
shikonin (1 mM) or insulin (1 mM) using the fluorescent ratiometric
Ca
2+ indicator indo-1. Cells were loaded with indo-1 by exposing
them to indo-1-AM (8.3 mM, Invitrogen) for 20 minutes followed
by at least 20 minutes of washing. Indo-1 was excited with light at
360 nm, and light emission at 40565 and 49565 nm was
measured with two photomultiplier tubes. The ratio (R) of the
light emission at 405 nm to that at 495 nm was converted to
[Ca
2+]i as described previously [26]. After establishing a baseline,
shikonin or insulin was added.
Figure 1. Shikonin increases glucose uptake in L6 myotubes.
(A) Glucose uptake in differentiated L6 myotubes in response to
100 nM, 1 mMo r1 0mM shikonin treatment (2 h). In (B) and (C), cells
were treated with 1 mM shikonin (sh) or 1 mM insulin (ins) for 2 h or
20 h respectively). Graphs show mean 6 SEM of four (A), seven (B) or
three (C) experiments. Asterisks represent statistical difference as
analyzed by one way ANOVA between basal and treated cells
(** P,0.01 *** P,0.001).
doi:10.1371/journal.pone.0022510.g001
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L6 cells stably transfected with GLUT4myc (kindly provided by
Prof. Amira Klip, University of Toronto, Canada) were plated in 4
well culture chamber slides (BD Biosciences, Franklin Lakes, BJ).
Cells were serum-starved 16 h before stimulation with insulin or
shikonin. Cells were washed with PBS after stimulation and fixed
for 5 min with 4% formaldehyde in PBS, and quenched with
50 mM glycine in PBS for 10 min. Cells were blocked with 5%
Figure 2. Akt-phosphorylation in response to shikonin and
insulin. (A) ImmunoblotoftotalAkt or phosphorylatedAktatserine473
(s473) or threonine 308 (t308) following treatment of L6 myotubes with
water as control (c) or stimulated with either 1 mM shikonin (sh) or 1 mM
insulin (ins) for 2 h. Figure is representative of three independent
experiments performed. (B) and (C) show quantification of immunoblots
expressed as a percentage of the response to 1 mM insulin (ins) for 2 h.
doi:10.1371/journal.pone.0022510.g002
Figure 3. Shikonin does not affect AMP-phosphorylation or
ATP/ADP-ratio. (A) Immunoblot phosphorylated AMPK at threonine
172 (t172) following treatment of L6 myotubes with water as control (c)
or stimulated with either 1 mM shikonin (sh) or 2 mM AICAR (ai) for 2 h.
Figure is representative of six independent experiments performed.(B)
Quantification of AMPK phosphorylation (t172) expressed as a
percentage of the basal levels. Asterisks represent statistical difference
as analyzed by one way ANOVAbetween basal and treated cells
(*** P,0.001). Graph show mean 6 SEM (n=6). (C) AMP to ATP-ratio in
L6 myotubes 1 mM shikonin or 1 mM DPI treatment. Graph show mean
6 SEM (n=4).
doi:10.1371/journal.pone.0022510.g003
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solution (1:200 dilution in 1.5% BSA in PBS) at 4uC overnight
followed by washing with PBS and 1 h incubation at room
temperature with Alexa Fluor 488-conjugated goat anti-rabbit IgG
secondary antibody (1:500 dilution, 1.5% BSA in PBS). Slides
were washed with PBS and mounted with ProLong Gold antifade
reagent (Invitrogen). Images were observed in a Confocal
microscope, ZEISS LSM 510 META. Quantification of immu-
nocytochemistry image was performed by using ImageJ program
(NIH).
Data analysis
All experiments were performed in singlicate or duplicate with n
referring to the number of independent experiments performed.
All results are expressed as mean 6 S.E.M. of n. Statistical analysis
was made with one-way ANOVA, using Tukey post hoc-test or
paired Student’s t-test, using Bonferroni’s correction for multiple
testing when appropriate.
Drugs and reagents
Shikonin was synthesised by Interchem (NJ, USA). Drugs and
reagents were purchased as follows: 2-deoxy-[
3H]-D-glucose
(12Ci/mmol, Amersham Biosciences, Buckinghamshire, UK);
insulin (ActrapidH) (Novo Nordisk, Bagsvaerd, Denmark); FCCP
(carbonyl cyanide p-trifluoromethoxyphenylhydrazone), 0.25%
trypsin in HBSS (Sigma); Fatty acid-free bovine serum albumin,
fraction V (Roche Diagnostics GmbH, Germany). All cell culture
medium and supplements were obtained from Sigma. All
antibodies were obtained from Cell Signaling Technology
(Beverly, MA, U.S.A.).
Results
Shikonin increases glucose uptake L6 myotubes
Shikonin increased glucose uptake (following 2 h of treatment)
in a concentration-dependent manner (Fig. 1A). A concentration
of 1 mM was found to give the highest increase (p,0.01) while
higher concentrations of shikonin ($10 mM) were found to cause
cell detachment (data not shown). This concentration of shikonin
(1 mM) is in the same order of magnitude as found to give the
highest glucose uptake response in rat cardiomyocytes, but lower
than that found for 3T3-L1 adipocytes [2], indicating muscles to
be highly sensitive to shikonin. Stimulation with shikonin (1 mM)
increased glucose uptake in L6-myotubes following 2 h of shikonin
treatment (p,0.01; Fig. 1B), which was the same magnitude of
response as that obtained following insulin treatment (1 mM,
p,0.01; Fig. 1B). Longer term treatment of cells with either
shikonin (1 mM) or insulin (1 mM) for 20 h showed no significant
increase in glucose uptake at this time point (there was a tendency
of shikonin and insulin to increase glucose uptake but this was not
Figure 4. Effects of shikonin on oxygen consumption. (A) Oxygen consumption measurements in L6 myotubes. Representative graph from
three independent measurements of oxygen consumption in L6 myotubes.1 mM shikonin was added as indicated. (B) Shikonin stimulated increase in
oxygen consumption in L6 myotubes expressed as percentage of basal. Graphs show mean 6 SEM from three independent experiments. (C) Oxygen
consumption in mitochondria from skeletal muscle in response to shikonin was measured in the absence (thin line) or presence (bold line) of
pyruvate. 10 mM shikonin was added as indicated.
doi:10.1371/journal.pone.0022510.g004
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effect is within hours and not long-term (Fig. 1C)).
Effect of shikonin on the phosphorylation of Akt
Shikonin increases Akt-phosphorylation in 3T3-L1 cells [2],
thus we wanted to investigate if shikonin also affected Akt
phosphorylation in L6 cells. In L6 myotubes shikonin treatment
(1 mM, 2 h) did not affect phosphorylation of Akt at residues s473
or t308 , as opposed to insulin (1 mM, 2 h) treatment which
increased phosphorylation of Akt at both residues (Fig. 2). This
indicates that in L6 myotubes, shikonin increases glucose uptake
independent of Akt-phosphorylation and thus act via a pathway
different than that of insulin.
Effect of shikonin on the phosphorylation of AMPK
One of the major insulin-independent regulators of glucose
uptake is AMPK. Thus we wanted to investigate the possible
activation of AMPK by shikonin. In L6 myotubes shikonin
treatment (1 mM, 2 h) did not affect phosphorylation of AMPK at
residue t172 as opposed to the pharmacological activator of
AMPK, AICAR (2 mM, 2 h), which increased AMPK phosphor-
ylation by ,2 fold (Fig. 3A and 3B).. Conversely, shikonin (1 mM
for 2 h) had no effect ont the AMP/ATP-ratio which was
increased by diphenyleneiodonium (DPI, 1 mM), which has
previously been shown to increase AMPK phosphorylation in L6
cells through increases in the AMP/ATP ration [27]((Fig. 3C).
Effect of shikonin on oxygen consumption in L6
myotubes
To investigate the effect of shikonin on overall cell metabolism
and the involvement of mitochondria, oxygen consumption rates
were monitored with a Clark-type oxygen electrode. Addition of
1 mM shikonin increased oxygen consumption in intact L6 muscle
cells (Fig. 4A). This acute effect was seen also when adding 1 mM
shikonin to cells that had been incubated with shikonin for 2 h (in
these experiment the final concentration of shikonin was 2 mM).
The average increase from three independent experiments was
16562% over basal (Fig. 4B). To test if this was due to uncoupling
and direct effect on mitochondria, measurement was performed
on mitochondria isolated from mouse skeletal muscle. Addition of
shikonin did not alter the rate of oxygen consumption in
mitochondria, either in the presence or the absence of the
substrate pyruvate indicating that shikonin does not act directly on
mitochondria (Fig. 4C).
Dependence of calcium on shikonin-mediated glucose
uptake
One possible mechanism to cause a rapid activation of oxygen
consumption is by altering the intracellular concentrations of
Ca
2+[28]. Increasing levels of A23187 (a calcium ionophore)
increased glucose uptake in a concentration-dependent manner in
L6 muscle cells to the same levels as insulin (Fig. 5A; concentrations
Figure 5. Calcium is involved in shikonin-medaited glucose
uptake. (A) Insulin and A23187 stimulated glucose uptake in L6 myotubes.
Data are mean 6SEM of three experiments (B) Measurement of intracellular
calcium levels by the fluorescent ratiometric Ca
2+ indicator indo-1 following
acute treatment with shikonin (1 mM) or insulin (1 mM). ***p,0.001,
*p,0.05, one way ANOVA . Graph show mean delta value 6 SEM of 15
experiments performed. Asterisks represent statistical difference as analyzed
by one way ANOVA between basal and treated cells (*p,0.05, *** P,0.001).
(C) Effect of BAPTA-AM on glucose uptake mediated by shikonin in L6
mytoubes. Cell were stimulated with shikonin for 2 h in the absence or
presence of 5 mM 1,2-Bis(2-aminophenoxy)ethane-N,N,N9,N9-tetraacetic acid
tetrakis(acetoxymethyl ester), BAPTA (BA). Graph show mean 6 SEM of 3
experiments performed. Asterisks represent statistical difference as analyzed
by one way ANOVA (*p,0.05, **,0.01).
doi:10.1371/journal.pone.0022510.g005
Table 1. Shikonin increases free calcium in L6-myotubes.
Resting (nM) Peak (nM) Delta (nM) P-value
Insulin 92691 0 5 610 1362 ,0.001
Shikonin 78679 8 692 0 66 ,0.005
Intracellular levels of calcium in L6 cells before and after acute exposure to
1 mM insulin or shikonin. Data are means 6 SEM (n=15).
doi:10.1371/journal.pone.0022510.t001
Shikonin Increase Glucose Uptake in Muscle
PLoS ONE | www.plosone.org 6 July 2011 | Volume 6 | Issue 7 | e22510higher than 1 mM of A23187 resulted in cell detachment (data not
shown)). To examine if shikonin increased calcium levels in L6
myotubes we utilized a fluorescent ratiometric Ca
2+-indicator, indo-
1. Shikonin gave a significant increase (p,0.001) in intracellular
calcium levels within minutes of shikonin addition to cells (Fig. 5B
and Table 1), as did insulin (1 mM, p,0.05). The changes in
calcium levels caused by shikonin and insulin were somewhat
different; while shikonin increased calcium almost instantly and to a
higher degree; the effect of insulin was more delayed (not shown).
To investigate the role of calcium in shikonin–mediated glucose
uptake, glucose uptake was assessed in the absence and presence of
the non-cell permeable calcium chelator 1,2-bis(2-aminophenox-
y)ethane-N,N,N9,N9-tetraacetic acid tetrakis acid (BAPTA) and its
cell-permeable analogue 1,2-Bis(2-aminophenoxy) ethane-
N,N,N9,N9-tetraacetic acid tetrakis-acetoxymethyl ester (BAPTA-
AM). When reducing extracellular calcium with BAPTA (5 mM,
5 min before stimulation), the effect of shikonin on glucose uptake
was unaltered (data not shown). In contrast, the cell permeable
analogue BAPTA-AM, (5 mM, 5 min before stimulation) reduced
shikonin stimulated glucose uptake in L6 myotubes (p,0.05)
(Fig. 5C).
Detection of GLUT4-translocation
There are several possible molecular mechanisms which lead
to increased glucose uptake into cells, of which the most
well-characterized in skeletal muscle is translocation of glucose
transporter GLUT4. In order to test if shikonin could affect
GLUT4-translocation, immunocytochemistry was performed in
L6 myoblasts. Insulin significantly stimulated GLUT4-transloca-
tion compared to basal (,2.5 fold increase in cell surface GLUT4
p,0.05). Shikonin in itself also significantly induced GLUT4
translocation (p,0.01) to the same extent as insulin (Fig. 6).
Shikonin administration to GK rats
To test the effect of shikonin on glucose homeostasis, GK rats
were used. During four days, GK-rats were treated with a daily i.p.
injection of shikonin (10 mg/kg). In the rats treated with shikonin
and placebo, the general condition, e.g. alertness and physical
activity, was observed to be normal during the whole experiment.
Plasma glucose levels were significantly lowered on 2
nd and 4
th
days compared to day 1(Fig. 7A). On the first day before i.p.
shikonin injection, the plasma glucose was 10.060.3 mM, and the
plasma glucose levels of the other consecutive days were
8.560.2and 7.560.2 mM, respectively (p,0.01 and p,0.001
compared to the first day). Also the areas under the glucose curve
(AUC) were significantly lower in shikonin treated rats compared
to control rats (24.960.8 vs 0.461.0-mM/3d, p=0.014).
In an insulin tolerance test, administration of insulin reduced
plasma glucose concentrations in all rats. The plasma glucose
levels prior to insulin injection were lower in the shikonin treated
rats compared to the control (p=0.007; Fig. 7B). Between 30–
240 min after injection of insulin, the AUCs were 39.36105.9 and
536.4 6144.0 mM/210 min, respectively (p,0.02).
Discussion
In this study we have investigated the effect of shikonin on
glucose uptake in L6 myotubes and examined its in vivo effect on
plasma glucose levels in diabetic GK-rats. We found that shikonin
increased glucose uptake to the same extent as insulin in L6
myotubes. In contrast to previous studies showing that shikonin
increases Akt-phosphorylation in 3T3-L1 adipocytes and CHO-
cells transfected with the insulin receptor [2,5], we found that in
L6 myotubes shikonin did not affect Akt-phosphorylation. These
results suggest that shikonin increases glucose uptake in myotubes
Figure 6. Shikonin stimulates translocation of GLUT4. (A) Representative confocal image of GLUT4-translocation which was detected by myc-
antibody in cells stable transfected with GLUT4myc after 2 h treatment with either 1 mM shikonin or 1 mM insulin (B) Quantification of confocal
images obtained in (A) by using Image J and expressed as % of basal. Graph show mean 6 SEM of 3 experiments performed. Asterisks represent
statistical difference as analyzed by one way ANOVA between basal and treated cells (***p,0.001, *p,0.05).
doi:10.1371/journal.pone.0022510.g006
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insulin-independent pathway regulating glucose uptake is AMPK.
AMPK functions as an energy sensor that can increase glucose
uptake and fatty acid oxidation when energy levels in a cell are
low. Due to its effect on glucose uptake, AMPK is a novel site for
the treatment of type 2 diabetes. However, in the present study,
measurement of AMP/ATP-levels showed no difference between
control and shikonin treated myotubes, nor was any increase in
phosphorylation of AMPK detected following shikonin treatment
observed, indicating that shikonin does not act via AMPK.
To examine whether shikonin increased glucose uptake in L6
cells through an increase in cellular respiration and thus an
elevated need for substrate, we tested if oxygen consumption rates
from L6 cells or isolated mouse skeletal muscle mitochondria
were altered following shikonin treatment. When adding shikonin
to L6 cells, the rate of oxygen consumption rapidly increased.
This is likely to lead to increased glucose uptake and could either
be due to increased cellular respiration or an uncoupling effect on
the mitochondria. Since shikonin had no effect on isolated
mousce skeletal muscle mitochondria, it is not likely to be an
uncoupler itself. One way to change mitochondria function is to
change ion-gradients, and accumulation of Ca
2+ into mitochon-
dria has been shown to cause a transient depolarisation of the
mitochondria membrane potential [28]. Measurement of intra-
cellular free calcium in L6 myotubes showed that shikonin
treatment in fact leads to an increase in free calcium levels. This
is very interesting since increased calcium levels are considered to
be one of the major events in contraction-mediated glucose
uptake in skeletal muscle [12]. Furthermore, calcium is shown to
increase glucose uptake in muscle cells also independently of
contraction [13]. We show that the calcium ionophore A23187
increases glucose uptake in L6 cells, confirming previous results
from both cell lines and primary myoblast cultures [14,15]. In our
study we also found that insulin treatment increased intracellular
calcium levels. The role of calcium in insulin signaling is debated,
but there are several studies showing calcium to be important for
late steps in the insulin signaling cascade, enabling docking and
fusion of GLUT4-containing vesicles to the plasma membrane
[30]. Studies in single muscle fibers from mice show that insulin
can increase calcium levels close to the plasma membrane
without affecting the global levels of free calcium [31]. This
means that even a small increase in whole cell calcium levels
possibly reflects a substantially local increase. In order to
investigate if the calcium-effect caused by shikonin leads to
increased glucose uptake, cells were pretreated with the calcium
chelator BAPTA and its cell permeable analogue BAPTA-AM
before stimulation with shikonin. Treatment with BAPTA-AM
(but not BAPTA) abolished the shikonin mediated glucose
uptake, suggesting shikonin to cause glucose uptake by increasing
intracellular calcium levels.
There are several possible molecular mechanisms whereby to
increase glucose uptake into cells. The most well-studied of those
is the translocation of the glucose transporter GLUT4. Upon
insulin-stimulation, as well as after AMPK-activation or muscle
contraction, GLUT4 is translocated from intracellular storages to
the plasma membrane. Surprisingly, we found that shikonin
treatment induced GLUT4-translocation in muscle cells to the
same extent as caused by insulin. This is a very exciting finding,
providing molecular proof of the end-mechanism utilized by
shikonin to increase glucose uptake. GLUT4-translocation has
previously been suggested to be calcium dependent, both in
insulin-action, as discussed above, as well as GLUT4-transloca-
tion due to muscle contraction [29]. We suggest here that the
increased calcium levels after shikonin treatment is important for
GLUT4-translocation although this is not investigated in this
study. We believe the effect of shikonin on GLUT4 translocation
is an important finding, because in the light of the increasing
prevalence of type 2 diabetes it is vital to find and characterize
insulin-independent pathways leading to glucose uptake. Im-
paired insulin signaling and GLUT4-translocation in peripheral
tissues is a major hallmark in diabetes. Interestingly, our current
findings show that shikonin uses the same end mechanism as
insulin (GLUT4-translocation), without using the same intracel-
lular signal (Akt-phosphorylation). Thus, there is a possibility that
shikonin could affect glucose uptake also in insulin-insensitive
muscles.
We formulated the hypothesis that shikonin could have
beneficial effect on plasma glucose in diabetic animals and chose
to test our hypothesis in diabetic GK rats. GK rats were injected
with shikonin daily for 4 days. No changes were observed in
general health conditions of the shikonin-treated rats, indicating
shikonin not to be detrimental to the animals, although we did
not examine possible toxic effects of long-term treatment. After
2 and 4 days of daily injection, lower plasma glucose levels were
found in shikonin treated rats. This finding shows for the first
time that shikonin has effects on glucose homeostasis. On day 4,
insulin injection lowered plasma glucose in both groups.
However, the absolute plasma glucose levels were lower in the
shikonin treated rats during the whole experiment. Thus, the
Figure 7. Shikonin injections lower plasma glucose levels in
diabetic GK-rats. (A) Shikonin effect on plasma glucose in GK-rats
treated with DMSO/oil (squares) or shikonin (10 mg/kg intraperitone-
ally) (triangles) for 4 days. Results are mean 6SEM of 6 rats.**p, 0.01
for shikonin day 2 compared to day 1, ***p,0.001 for shikonin day 4
compared to day 1 (Students t-test). (B) Shikonin effect on insulin
sensitivity in GK-rats. Plasma glucose was measured in GK-rats after s.c.
insulin in GK rats treated with DMSO/oil (squares) or shikonin (triangles)
for 4 days. Results are mean 6SEM of 6 rats.
doi:10.1371/journal.pone.0022510.g007
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direction that shikonin and insulin acts via different pathways.
Thus the current data supports our conclusions from skeletal
muscle cells.
Although our main focus has been on skeletal muscle, it is
possible that shikonin has several beneficial effects in diabetic
animals. Since shikonin has previously been reported to increase
glucose uptake and enhance insulin signaling in 3T3-L1 and
primary adipocytes [2], and inhibit fat accumulation in 3T3-L1
adipocytes [3], it is possible that in addition to the effects in
muscle, shikonin increases insulin sensitization in fat tissue.
Furthermore, shikonin is shown to inhibit NADPH-oxidase, a
membrane bound enzyme complex that catalyses the formation
of ROS in leukocytes [32], and such inhibition could potentially
increase the insulin sensitivity due to a suppression of
inflammation [33]. However, our present data suggest that the
major effect of shikonin in vivo did not increase insulin-
sensitization. The fold change in plasma glucose levels after
insulin injection in GK-rats is in the same order of magnitude
for the shikonin-treated animals as for the control. This would
indicate that insulin stimulates glucose uptake to the same
degree in control and the treated animals. This, together with
our results from L6 cells, as well as the fact that skeletal muscle
is a major site for glucose clearing, suggests that the main effect
of shikonin, to decrease plasma glucose levels in vivo,i st h r o u g h
glucose uptake in skeletal muscle.
In conclusion, we have shown that shikonin increases glucose
uptake in L6 skeletal muscle cells by an insulin-independent
mechanism involving increased intracellular calcium levels and
GLUT4-translocation. Since insulin signaling is impaired in type 2
diabetes it is of great interest to find molecules and mechanisms
that regulates glucose uptake in peripheral tissues. Due to the large
proportion of skeletal muscle in the body, inducing glucose uptake
in this tissue can have large effects on plasma glucose levels. Our
results indeed show that shikonin has beneficial effects on plasma
glucose levels in diabetic GK rats, indicating that this compound
or its derivates could be important molecules in the search for
novel therapy of type 2 diabetes.
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